BTIG Maintains Buy on vTv Therapeutics, Raises Price Target to $49
Benzinga Newsdesk 9 months ago
NewsPrice TargetAnalyst Ratings
BTIG analyst Kambiz Yazdi maintains vTv Therapeutics (NASDAQ:VTVT) with a Buy and raises the price target from $40 to $49.
BTIG analyst Kambiz Yazdi maintains vTv Therapeutics (NASDAQ:VTVT) with a Buy and raises the price target from $40 to $49.